Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …

Hypoxia induicible factor-1 alpha (HIF-1α) is a key transcription factor in cancer progression
and target therapy in cancer. HIF-1α acts differently depending on presence or absence of …

Clear-cell carcinomas (CCCs) are a histological group of highly aggressive malignancies
commonly originating in the kidney and ovary. CCCs are distinguished by aberrant lipid and …

Intratumoral hypoxia (reduced O 2 availability) is a common finding in human cancer and
leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression …

Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …

Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell
renal cell carcinomas (ccRCCs), leading to inappropriate stabilization of hypoxia-inducible …

There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

Upon exposure to stress, tRNAs are enzymatically cleaved, yielding distinct classes of tRNA-
derived fragments (tRFs). We identify a novel class of tRFs derived from tRNA Glu, tRNA …

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …

Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors
with limited molecular and clinical characterization. Emerging evidence suggests immune …